{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T12:47:05Z","timestamp":1759063625824,"version":"3.37.3"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005788","name":"Medical University of Vienna","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005788","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2021,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Purpose<\/jats:title>\n                <jats:p>Data on the efficacy, dosing and safety of letermovir for the compassionate therapeutic use of CMV infections are limited.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Clinical and virological efficacy of letermovir was assessed in a retrospective single-centre study of patients who received letermovir for the compassionate therapeutic use of CMV infections.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Letermovir initiation yielded prompt treatment response in 7 out of 9 patients (77.7%).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Letermovir may be an effective and well tolerated option in the compassionate treatment of CMV infections, although recurrence of CMV and emergence of resistance may be issues.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10096-020-03990-w","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T23:05:06Z","timestamp":1599779106000},"page":"435-439","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Letermovir for the compassionate therapeutic use of cytomegalovirus infection"],"prefix":"10.1007","volume":"40","author":[{"given":"Lorenz","family":"Schubert","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Fisecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz","family":"Burgmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3500-7205","authenticated-orcid":false,"given":"Christoph","family":"Steininger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"3990_CR1","doi-asserted-by":"publisher","first-page":"900","DOI":"10.1097\/TP.0000000000002191","volume":"102","author":"CN Kotton","year":"2018","unstructured":"Kotton CN, Kumar D, Caliendo AM, Huprikar S, Chou S, Danziger-Isakov L et al (2018) The third international consensus guidelines on the management of cytomegalovirus in solid-organ transplantation. Transplantation 102:900\u2013931. https:\/\/doi.org\/10.1097\/TP.0000000000002191","journal-title":"Transplantation"},{"key":"3990_CR2","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1128\/CMR.00009-10","volume":"23","author":"NS Lurain","year":"2010","unstructured":"Lurain NS, Chou S (2010) Antiviral drug resistance of human cytomegalovirus. Clin Microbiol Rev 23:689\u2013712. https:\/\/doi.org\/10.1128\/CMR.00009-10","journal-title":"Clin Microbiol Rev"},{"key":"3990_CR3","doi-asserted-by":"publisher","first-page":"2433","DOI":"10.1056\/NEJMoa1706640","volume":"377","author":"FM Marty","year":"2017","unstructured":"Marty FM, Ljungman P, Chemaly RF, Maertens J, Dadwal SS, Duarte RF, Haider S, Ullmann AJ, Katayama Y et al (2017) Letermovir prophylaxis for cytomegalovirus in hematopoietic-cell transplantation. N Engl J Med 377:2433\u20132444. https:\/\/doi.org\/10.1056\/NEJMoa1706640","journal-title":"N Engl J Med"},{"key":"3990_CR4","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/femsre\/fuy004","volume":"42","author":"G Ligat","year":"2018","unstructured":"Ligat G, Cazal R, Hantz S, Alain S (2018) The human cytomegalovirus terminase complex as an antiviral target: a close-up view. FEMS Microbiol Rev 42:137\u2013145. https:\/\/doi.org\/10.1093\/femsre\/fuy004","journal-title":"FEMS Microbiol Rev"},{"key":"3990_CR5","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1111\/j.1600-6143.2011.03530.x","volume":"11","author":"DR Kaul","year":"2011","unstructured":"Kaul DR, Stoelben S, Cober E, Ojo T, Sandusky E, Lischka P et al (2011) First report of successful treatment of multidrug-resistant cytomegalovirus disease with the novel anti-CMV compound AIC246. Am J Transplant 11:1079\u20131084. https:\/\/doi.org\/10.1111\/j.1600-6143.2011.03530.x","journal-title":"Am J Transplant"},{"key":"3990_CR6","doi-asserted-by":"publisher","unstructured":"Turner N, Strand A, Grewal DS, Cox G, Arif S, Baker AW et al (2019) Use of letermovir as salvage therapy for drug-resistant cytomegalovirus retinitis. Antimicrob Agents Chemother 63. https:\/\/doi.org\/10.1128\/AAC.02337-18","DOI":"10.1128\/AAC.02337-18"},{"key":"3990_CR7","doi-asserted-by":"publisher","unstructured":"Phoompoung P, Ferreira VH, Tikkanen J, Husain S, Viswabandya A, Kumar D et al (2020) Letermovir as salvage therapy for cytomegalovirus infection in transplant recipients. Transplantation. https:\/\/doi.org\/10.1097\/TP.0000000000002785","DOI":"10.1097\/TP.0000000000002785"},{"key":"3990_CR8","doi-asserted-by":"publisher","unstructured":"Ljungman P, Boeckh M, Hirsch HH, Josephson F, Lundgren J, Nichols G et al (2017) Definitions of cytomegalovirus infection and disease in transplant patients for use in clinical trials. Clin Infect Dis. https:\/\/doi.org\/10.1093\/cid\/ciw668","DOI":"10.1093\/cid\/ciw668"},{"key":"3990_CR9","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1086\/342601","volume":"186","author":"A Humar","year":"2002","unstructured":"Humar A, Kumar D, Boivin G, Caliendo AM (2002) Cytomegalovirus (CMV) virus load kinetics to predict recurrent disease in solid-organ transplant patients with CMV disease. J Infect Dis 186:829\u2013833. https:\/\/doi.org\/10.1086\/342601","journal-title":"J Infect Dis"},{"key":"3990_CR10","doi-asserted-by":"publisher","first-page":"3060","DOI":"10.1111\/ajt.15135","volume":"18","author":"L Cherrier","year":"2018","unstructured":"Cherrier L, Nasar A, Goodlet KJ, Nailor MD, Tokman S, Chou S (2018) Emergence of letermovir resistance in a lung transplant recipient with ganciclovir-resistant cytomegalovirus infection. Am J Transplant 18:3060\u20133064. https:\/\/doi.org\/10.1111\/ajt.15135","journal-title":"Am J Transplant"},{"key":"3990_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1093\/infdis\/jiv352","volume":"213","author":"P Lischka","year":"2016","unstructured":"Lischka P, Michel D, Zimmermann H (2016) Characterization of cytomegalovirus breakthrough events in a phase 2 prophylaxis trial of letermovir (AIC246, MK 8228). J Infect Dis 213:23\u201330. https:\/\/doi.org\/10.1093\/infdis\/jiv352","journal-title":"J Infect Dis"},{"key":"3990_CR12","doi-asserted-by":"publisher","unstructured":"Jung S, Michel M, Stamminger T, Michel D (2019) Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient. BMC Infect Dis 19. https:\/\/doi.org\/10.1186\/s12879-019-4016-1","DOI":"10.1186\/s12879-019-4016-1"},{"key":"3990_CR13","doi-asserted-by":"publisher","unstructured":"Douglas CM, Barnard R, Holder D, Leavitt R, Levitan D, Maguire M et al (2020) Letermovir resistance analysis in a clinical trial of cytomegalovirus prophylaxis for hematopoietic stem cell transplant recipients. J Infect Dis. https:\/\/doi.org\/10.1093\/infdis\/jiz577","DOI":"10.1093\/infdis\/jiz577"},{"key":"3990_CR14","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/tri.12225","volume":"27","author":"S Stoelben","year":"2014","unstructured":"Stoelben S, Arns W, Renders L, Hummel J, M\u00fchlfeld A, Stangl M et al (2014) Preemptive treatment of Cytomegalovirus infection in kidney transplant recipients with letermovir: results of a phase 2a study. Transpl Int 27:77\u201386. https:\/\/doi.org\/10.1111\/tri.12225","journal-title":"Transpl Int"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-020-03990-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-020-03990-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,11]],"date-time":"2021-09-11T01:37:11Z","timestamp":1631324231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-020-03990-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["3990"],"URL":"https:\/\/doi.org\/10.1007\/s10096-020-03990-w","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2020,9,11]]},"assertion":[{"value":"16 May 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Ethical approval was waived by the local Ethics Committee of the Medical University Austria in view of the retrospective nature of the study, and all the procedures being performed were part of the routine care.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}